Skip to main content

Advertisement

SpringerLink
Log in

Patch Testing in the Diagnosis of Medication Allergy

  • Contact Dermatitis (S Jacob, Section Editor)
  • Published:
Current Treatment Options in Allergy Aims and scope Submit manuscript

Opinion statement

In evaluation of medication allergy, the utility of drug patch testing is dependent on both the type of drug reaction and the suspected causal drug. Epicutaneous patch tests reproduce T cell-mediated delayed hypersensitivity; thus, eruptions at least partially mediated by T cells can be confirmed by positive drug patch test (DPT) responses in some patients. These include acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS), fixed drug eruptions (FDE), macular drug reactions (“morbilliform” or “exanthematous” reactions), and Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). Currently, literature supports that specific drugs, including antiepileptics and certain antibiotics, are most likely to produce diagnostic patch test results. However, drug patch testing cannot be used reliably for all medications. We suggest that standardized international guidelines should be developed and implemented to improve the comparability of results from drug patch testing reported in literature. Furthermore, an organized, systematic research strategy should be executed in order to gain further understanding of how and when drug patch testing can be used most effectively.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Balachandran C, Shenoi SD, Sarkar D, Ravikumar BC. Patch tests in adverse cutaneous drug reaction. Indian J Dermatol Venereol Leprol. 2002;68(1):13–5.

    CAS  PubMed  Google Scholar 

  2. Friedmann PS, Ardern-Jones M. Patch testing in drug allergy. Curr Opin Allergy Clin Immunol. 2010;10(4):291–6. doi:10.1097/ACI.0b013e32833aa54d.

    Article  CAS  PubMed  Google Scholar 

  3. Barbaud A, Goncalo M, Bruynzeel D, Bircher A. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis. 2001;45(6):321–8.

    Article  CAS  PubMed  Google Scholar 

  4. Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy. 2002;57(1):45–51.

    CAS  PubMed  Google Scholar 

  5. Chiang A, Maibach HI. Towards a perfect vehicle(s) for diagnostic patch testing: an overview. Cutan Ocul Toxicol. 2013;32(1):60–6. doi:10.3109/15569527.2012.684418.

    Article  PubMed  Google Scholar 

  6. Barrantes-Gonzalez M, Espona-Quer M, Salas E, Gimenez-Arnau AM. Bisphosphonate-induced cutaneous adverse events: the difficulty of assessing imputability through patch testing. Dermatology. 2014;229(3):163–8. doi:10.1159/000363382.

    Article  CAS  PubMed  Google Scholar 

  7. Barbaud A. Skin testing and patch testing in non-IgE-mediated drug allergy. Curr Allergy Asthma Rep. 2014;14(6):442. doi:10.1007/s11882-014-0442-8. This study represents one of the largest prospective multicenter studies conducted to evaluate the utility of drug patch testing in the diagnosis AGEP, DRESS and SJS/TEN. The authors followed guidelines previously published by Barbaud to produce patch test results with greater standardization.

    Article  PubMed  Google Scholar 

  8. Barbaud A, Collet E, Milpied B, Assier H, Staumont D, Avenel-Audran M, Grange A, Amarger S, Girardin P, Guinnepain MT, Truchetet F, Lasek A, Waton J. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol. 2013;168(3):555–62. doi:10.1111/bjd.12125.

    Article  CAS  PubMed  Google Scholar 

  9. Wolkenstein P, Chosidow O, Flechet ML, Robbiola O, Paul M, Dume L, Revuz J, Roujeau JC. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis. 1996;35(4):234–6.

    Article  CAS  PubMed  Google Scholar 

  10. Syrigou E, Grapsa D, Charpidou A, Syrigos K. Acute generalized exanthematous pustulosis induced by amoxicillin/clavulanic acid: report of a case presenting with generalized lymphadenopathy. J Cutan Med Surg. 2015;19(6):592–4. doi:10.1177/1203475415588003.

    Article  CAS  PubMed  Google Scholar 

  11. Bomarrito L, Zisa G, Delrosso G, Farinelli P, Galimberti M. A case of acute generalized exanthematous pustulosis due to amoxicillin-clavulanate with multiple positivity to beta-lactam patch testing. Eur Ann Allergy Clin Immunol. 2013;45(5):178–80.

    CAS  PubMed  Google Scholar 

  12. Chaabane A, Aouam K, Gassab L, Njim L, Boughattas NA. Acute generalized exanthematous pustulosis (AGEP) induced by cefotaxime. Fundam Clin Pharmacol. 2010;24(4):429–32. doi:10.1111/j.1472-8206.2009.00794.x.

    Article  PubMed  Google Scholar 

  13. O’Toole A, Lacroix J, Pratt M, Beecker J. Acute generalized exanthematous pustulosis associated with 2 common medications: hydroxyzine and benzocaine. J Am Acad Dermatol. 2014;71(4):e147–9. doi:10.1016/j.jaad.2014.05.041.

    Article  PubMed  Google Scholar 

  14. Alava-Cruz C, Rojas Perez-Ezquerra P, Pelta-Fernandez R, Zubeldia-Ortuno JM, de Barrio-Fernandez M. Acute generalized exanthematous pustulosis due to benznidazole. J Allergy Clin Immunol Pract. 2014;2(6):800–2. doi:10.1016/j.jaip.2014.08.003.

    Article  PubMed  Google Scholar 

  15. Shin HT, Park SW, Lee KT, Park HY, Park JH, Lee DY, Lee JH, Yang JM, Lee ES. A case of celecoxib induced acute generalized exanthematous pustulosis. Ann Dermatol. 2011;23(Suppl 3):S380–2. doi:10.5021/ad.2011.23.S3.S380.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Yang CC, Lee JY, Chen WC. Acute generalized exanthematous pustulosis caused by celecoxib. J Formos Med Assoc. 2004;103(7):555–7.

    PubMed  Google Scholar 

  17. Mashiah J, Brenner S. A systemic reaction to patch testing for the evaluation of acute generalized exanthematous pustulosis. Arch Dermatol. 2003;139(9):1181–3. doi:10.1001/archderm.139.9.1181.

    Article  PubMed  Google Scholar 

  18. Santiago F, Goncalo M, Vieira R, Coelho S, Figueiredo A. Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS). Contact Dermatitis. 2010;62(1):47–53. doi:10.1111/j.1600-0536.2009.01659.x.

    Article  CAS  PubMed  Google Scholar 

  19. Ohtoshi S, Kitami Y, Sueki H, Nakada T. Utility of patch testing for patients with drug eruption. Clin Exp Dermatol. 2014;39(3):279–83. doi:10.1111/ced.12239. This retrospective study analyzes the utility of drug patch testing in patients with severe adverse cutaneous drug reactions over a twenty-year period.

    Article  CAS  PubMed  Google Scholar 

  20. Elzagallaai AA, Knowles SR, Rieder MJ, Bend JR, Shear NH, Koren G. Patch testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review. Drug Saf. 2009;32(5):391–408. doi:10.2165/00002018-200932050-00003.

    Article  CAS  PubMed  Google Scholar 

  21. Galindo PA, Borja J, Gomez E, Mur P, Gudin M, Garcia R, Encinas C, Romero G, Garrido JA, Cortina P, Feo F. Anticonvulsant drug hypersensitivity. J Investig Allergol Clin Immunol. 2002;12(4):299–304.

    CAS  PubMed  Google Scholar 

  22. Lin YT, Chang YC, Hui RC, Yang CH, Ho HC, Hung SI, Chung WH. A patch testing and cross-sensitivity study of carbamazepine-induced severe cutaneous adverse drug reactions. J Eur Acad Dermatol Venereol. 2013;27(3):356–64. doi:10.1111/j.1468-3083.2011.04418.x. This study supports the use of drug patch testing as a diagnostic test for carbamazepine induced SJS/TEN and DRESS.

    Article  CAS  PubMed  Google Scholar 

  23. Buyuktiryaki AB, Bezirganoglu H, Sahiner UM, Yavuz ST, Tuncer A, Kara A, Sackesen C. Patch testing is an effective method for the diagnosis of carbamazepine-induced drug reaction, eosinophilia and systemic symptoms (DRESS) syndrome in an 8-year-old girl. Aust J Dermatol. 2012;53(4):274–7. doi:10.1111/j.1440-0960.2012.00887.x.

    Article  Google Scholar 

  24. Cabanas R, Calderon O, Ramirez E, Fiandor A, Prior N, Caballero T, Herranz P, Bobolea I, Lopez-Serrano MC, Quirce S, Bellon T. Piperacillin-induced DRESS: distinguishing features observed in a clinical and allergy study of 8 patients. J Investig Allergol Clin Immunol. 2014;24(6):425–30.

    CAS  PubMed  Google Scholar 

  25. Brahimi N, Routier E, Raison-Peyron N, Tronquoy AF, Pouget-Jasson C, Amarger S, Machet L, Amsler E, Claeys A, Sassolas B, Leroy D, Grange A, Dupuy A, Cordel N, Bonnetblanc JM, Milpied B, Doutre MS, Guinnepain MT, Barbaud A, Chosidow O, Roujeau JC, Lebrun-Vignes B, Descamps V. A three-year-analysis of fixed drug eruptions in hospital settings in France. Eur J Dermatol. 2010;20(4):461–4. doi:10.1684/ejd.2010.0980.

    PubMed  Google Scholar 

  26. Andrade P, Brinca A, Goncalo M. Patch testing in fixed drug eruptions--a 20-year review. Contact Dermatitis. 2011;65(4):195–201. doi:10.1111/j.1600-0536.2011.01946.x.

    Article  PubMed  Google Scholar 

  27. Tornero P, De Barrio M, Baeza ML, Herrero T. Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing. Contact Dermatitis. 2004;51(2):57–62. doi:10.1111/j.0105-1873.2004.00274.x.

    Article  CAS  PubMed  Google Scholar 

  28. Grandhe NP, Kaur I, Parsad D, Dogra S. Role of patch testing in antimicrobial drug eruptions. Contact Dermatitis. 2004;50(4):259–61. doi:10.1111/j.0105-1873.2004.0301j.x.

    Article  PubMed  Google Scholar 

  29. Calistru AM, Cunha AP, Nogueira A, Azevedo F. Etoricoxib-induced fixed drug eruption with positive lesional patch tests. Cutan Ocul Toxicol. 2011;30(2):154–6. doi:10.3109/15569527.2010.521226.

    Article  CAS  PubMed  Google Scholar 

  30. Andrade P, Goncalo M. Fixed drug eruption caused by etoricoxib--2 cases confirmed by patch testing. Contact Dermatitis. 2011;64(2):118–20. doi:10.1111/j.1600-0536.2010.01847.x.

    Article  PubMed  Google Scholar 

  31. Ponce V, Munoz-Bellido F, Moreno E, Laffond E, Gonzalez A, Davila I. Fixed drug eruption caused by etoricoxib with tolerance to celecoxib and parecoxib. Contact Dermatitis. 2012;66(2):107–8. doi:10.1111/j.1600-0536.2011.01982.x.

    Article  PubMed  Google Scholar 

  32. Gomez de la Fuente E, Pampin Franco A, Caro Gutierrez D, Lopez Estebaranz JL. Fixed drug eruption due to etoricoxib in a patient with tolerance to celecoxib: the value of patch testing. Actas Dermosifiliogr. 2014;105(3):314–5. doi:10.1016/j.adengl.2013.04.022.

    Article  CAS  PubMed  Google Scholar 

  33. Malheiro D, Cadinha S, Rodrigues J, Vaz M, Castel-Branco MG. Nimesulide-induced fixed drug eruption. Allergol Immunopathol (Madr). 2005;33(5):285–7.

    Article  CAS  Google Scholar 

  34. Zaiem A, Kaabi W, Badri T, Lakhoua G, Sahnoun R, Kastalli S, Daghfous R, Lakhal M, El Aidli S. Meprobamate-induced fixed drug eruption. Curr Drug Saf. 2014;9(2):161–2.

    Article  CAS  PubMed  Google Scholar 

  35. Delaigue S, Boye T, Pasquine C, Guetta K, Alla P, Ponte-Astoul J, Morand JJ. Drug patch tests in the investigation of a fixed drug eruption subsequent to 2 courses of cyclophosphamide in combination with mesna. Ann Dermatol Venereol. 2015;142(1):37–40. doi:10.1016/j.annder.2014.06.013.

    Article  CAS  PubMed  Google Scholar 

  36. Sanchez-Morillas L, Rojas Perez-Ezquerra P, Gonzalez Morales ML, Gonzalez-Mendiola R, Laguna Martinez JJ. Fixed drug eruption due to ibuprofen with patch test positive on the residual lesion. Allergol Immunopathol (Madr). 2013;41(3):203–4. doi:10.1016/j.aller.2012.04.007.

    Article  CAS  Google Scholar 

  37. Kai Y, Okamoto O, Fujiwara S. Fixed drug eruption caused by three unrelated drugs: promethazine, pethidine and omeprazole. Clin Exp Dermatol. 2011;36(7):755–8. doi:10.1111/j.1365-2230.2011.04093.x.

    Article  CAS  PubMed  Google Scholar 

  38. Romano A, Di Fonso M, Papa G, Pietrantonio F, Federico F, Fabrizi G, Venuti A. Evaluation of adverse cutaneous reactions to aminopenicillins with emphasis on those manifested by maculopapular rashes. Allergy. 1995;50(2):113–8.

    Article  CAS  PubMed  Google Scholar 

  39. Romano A, Viola M, Mondino C, Pettinato R, Di Fonso M, Papa G, Venuti A, Montuschi P. Diagnosing nonimmediate reactions to penicillins by in vivo tests. Int Arch Allergy Immunol. 2002;129(2):169–74.

    Article  CAS  PubMed  Google Scholar 

  40. Pereira N, Canelas MM, Santiago F, Brites MM, Goncalo M. Value of patch tests in clindamycin-related drug eruptions. Contact Dermatitis. 2011;65(4):202–7. doi:10.1111/j.1600-0536.2011.01942.x.

    Article  PubMed  Google Scholar 

  41. Barbaud A, Trechot P, Weber-Muller F, Ulrich G, Commun N, Schmutz JL. Drug skin tests in cutaneous adverse drug reactions to pristinamycin: 29 cases with a study of cross-reactions between synergistins. Contact Dermatitis. 2004;50(1):22–6. doi:10.1111/j.0105-1873.2004.00280.x.

    Article  CAS  PubMed  Google Scholar 

  42. Endo JO, Davis C, Powell DL. The potential utility of patch testing in identifying the causative agent of morbilliform drug eruptions. Dermatitis : Contact, Atopic, Occupational, Drug. 2011;22(2):114–5.

    Google Scholar 

  43. Vinas M, Castillo MJ, Hernandez N, Ibero M. Cutaneous drug eruption induced by antihistamines. Clin Exp Dermatol. 2014;39(8):918–20. doi:10.1111/ced.12445.

    Article  CAS  PubMed  Google Scholar 

  44. Bernedo N, Gonzalez I, Gastaminza G, Audicana M, Fernandez E, Munoz D. Positive patch test in vancomycin allergy. Contact Dermatitis. 2001;45(1):43.

    Article  CAS  PubMed  Google Scholar 

  45. Dalmau J, Serra-Baldrich E, Roe E, Lopez-Lozano HE, Alomar A. Skin reaction to hydroxyzine (Atarax): patch test utility. Contact Dermatitis. 2006;54(4):216–7. doi:10.1111/j.0105-1873.2006.0775d.x.

    Article  PubMed  Google Scholar 

  46. Atanaskovic-Markovic M, Medjo B, Gavrovic-Jankulovic M, Cirkovic Velickovic T, Nikolic D, Nestorovic B. Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Pediatr Allergy Immunol. 2013;24(7):645–9. doi:10.1111/pai.12121.

    Article  PubMed  Google Scholar 

  47. Barbaud A. Skin testing in delayed reactions to drugs. Immunol Allergy Clin N Am. 2009;29(3):517–35. doi:10.1016/j.iac.2009.04.010.

    Article  Google Scholar 

  48. Shebe K, Ngwanya MR, Gantsho N, Lehloenya RJ. Severe recurrence of drug rash with eosinophilia and systemic symptoms syndrome secondary to rifampicin patch testing in a human immunodeficiency virus-infected man. Contact Dermatitis. 2014;70(2):125–7. doi:10.1111/cod.12155.

    Article  PubMed  Google Scholar 

  49. Lehloenya RJ, Todd G, Wallace J, MR N, Muloiwa R, Dheda K. Diagnostic patch testing following tuberculosis-associated cutaneous adverse drug events induces systemic reactions in HIV-infected persons. Br J Dermatol. 2016. doi:10.1111/bjd.14492.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical College of Georgia, Augusta University, 1004 Chafee Avenue, FH 100, Augusta, GA, USA

    Kerrie Grunnet BS

  2. Division of Dermatology, Department of Medicine, Medical College of Georgia, Augusta University, 1004 Chafee Avenue, FH 100, Augusta, GA, USA

    Jake E. Turrentine MD

Authors
  1. Kerrie Grunnet BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jake E. Turrentine MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jake E. Turrentine MD.

Ethics declarations

Conflict of Interest

Kerrie Grunnet and Dr. Jake Turrentine declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Contact Dermatitis

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grunnet, K., Turrentine, J.E. Patch Testing in the Diagnosis of Medication Allergy. Curr Treat Options Allergy 3, 310–321 (2016). https://doi.org/10.1007/s40521-016-0088-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40521-016-0088-y

Keywords

Search

Navigation